Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable-polymer coronary stent - five-year results of the TARGET All Comers randomised clinical trial.
Lansky AJ, Xu B, Baumbach A, Kelbæk H, van Royen N, Zheng M, Knaapen P, Slagboom T, Johnson TW, Vlachojannis GJ, Arkenbout KE, Holmvang L, Janssens L, Brugaletta S, Naber CK, Schmitz T, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina CM, Buszman PE, Thiele H, Schächinger V, Wijns W. Lansky AJ, et al. Among authors: brugaletta s. EuroIntervention. 2023 Dec 4;19(10):e844-e855. doi: 10.4244/EIJ-D-23-00409. EuroIntervention. 2023. PMID: 37860860 Free PMC article. Clinical Trial.
Endothelial progenitor cell capturing stent and short dual antiplatelet therapy in patients on chronic anti-vitamin k regimen undergoing percutaneous coronary interventions: long-term outcomes of a single centre registry.
Martin-Yuste V, Brugaletta S, Ferreira-González I, Cola C, Alvarez-Contreras L, de Antonio M, Martí V, García-Picart J, Sabaté M. Martin-Yuste V, et al. Among authors: brugaletta s. EuroIntervention. 2011 Feb;6(7):831-7. doi: 10.4244/EIJV6I7A143. EuroIntervention. 2011. PMID: 21252017
Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study.
Gomez-Lara J, Diletti R, Brugaletta S, Onuma Y, Farooq V, Thuesen L, McClean D, Koolen J, Ormiston JA, Windecker S, Whitbourn R, Dudek D, Dorange C, Veldhof S, Rapoza R, Regar E, Garcia-Garcia HM, Serruys PW. Gomez-Lara J, et al. Among authors: brugaletta s. EuroIntervention. 2012 Jun 20;8(2):214-24. doi: 10.4244/EIJV8I2A35. EuroIntervention. 2012. PMID: 22030265
Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction.
Sabaté M, Cequier A, Iñiguez A, Serra A, Hernández-Antolín R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vázquez N, Brugaletta S, Backx B, Serruys P. Sabaté M, et al. Among authors: brugaletta s. EuroIntervention. 2011 Dec;7(8):977-84. doi: 10.4244/EIJV7I8A154. EuroIntervention. 2011. PMID: 22115622 Free article. Clinical Trial.
Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION trial.
Brugaletta S, Sabate M, Martin-Yuste V, Masotti M, Shiratori Y, Alvarez-Contreras L, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gomez-Lara J, Backx B, Serruys PW. Brugaletta S, et al. Int J Cardiol. 2013 Oct 3;168(3):2632-6. doi: 10.1016/j.ijcard.2013.03.036. Epub 2013 Apr 8. Int J Cardiol. 2013. PMID: 23578890 Clinical Trial.
Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S. Sabaté M, et al. Among authors: brugaletta s. JACC Cardiovasc Interv. 2014 Jan;7(1):55-63. doi: 10.1016/j.jcin.2013.07.012. Epub 2013 Dec 11. JACC Cardiovasc Interv. 2014. PMID: 24332419 Free article.
Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials.
Taniwaki M, Stefanini GG, Räber L, Brugaletta S, Cequier A, Heg D, Iñiguez A, Kelbæk H, Serra A, Ostoijic M, Hernandez-Antolin R, Baumbach A, Blöchlinger S, Jüni P, Mainar V, Sabate M, Windecker S. Taniwaki M, et al. Among authors: brugaletta s. EuroIntervention. 2015 Aug;11(4):391-8. doi: 10.4244/EIJY14M07_12. EuroIntervention. 2015. PMID: 25042419 Free article.
400 results